Health · Pharma & Biotech · 1 hr ago
Kymera to release mid-stage eczema trial results before year-end
Dupixent, made by Sanofi and Regeneron, is a leading immunology drug used by 1.4 million patients for conditions including eczema and asthma.
Kymera Therapeutics is testing KT-621 as a potential rival to the blockbuster treatment.
The Massachusetts biotech plans to release results from a mid-stage trial of KT-621 in eczema before the end of the year.
The results could shape the drug’s prospects and affect Kymera and other companies competing in the field.
A successful trial could also support plans to test KT-621 for chronic spontaneous urticaria and asthma.
Investors and doctors are watching for the readout, which could clarify whether the drug may become a treatment option for people with eczema.
Kymera Therapeutics plans to announce results from a mid-stage trial of its eczema drug KT-621 before the end of 2026.
The results are a high-stakes test of the experimental therapy’s potential to rival Dupixent, the top-selling drug in immunology.
The findings could affect Kymera, its competitors and the company’s plans to pursue other immune diseases.
Analysts forecast KT-621 sales could reach nearly $4 billion by 2035, including more than $3 billion in eczema revenue.
- Who
- Massachusetts biotech Kymera Therapeutics.
- What
- It plans to release results from a mid-stage clinical trial of KT-621 in eczema.
- When
- Before the end of 2026.
- Where
- The trial location is not stated.
- Why
- The results will test the drug’s potential as a treatment for eczema and could inform its use against other immune diseases.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Drug candidate
- KT-621
- Trial stage
- Mid-stage clinical trial
- Planned results
- Before the end of 2026
- Forecast sales by 2035
- Nearly $4 billion
- Forecast eczema revenue by 2035
- More than $3 billion
1 source
What people are saying
one of the most impactful I&I readouts this year